REPL - Conference and earnings call announcements

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the d

WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2026. The Company has two abstracts selected for oral presentation, including a 3-year landmark overall survival analysis from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and an oral presentation on the final safety, efficacy, and biomarker results from the Phase 1 first-in-human study of RP2

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Leerink Partners 2026 Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 2:20 pm EDT Jefferies 2026 Biotech on the Beach SummitDate: Tuesday, March 10, 20261x1 Meetings Live webcasts of the fireside chat will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About ReplimuneReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the developmen

WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of

WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO 2024 Oncology SummitDate: Tuesday, October 8, 2024 3rd Annual Roth Healthcare Opportunities Conference Date: Wednesday, October 9, 2024 About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune's proprietary RPx

WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences: BTIG Virtual Biotechnology Conference Dates: August 5-6, 2024 2024 Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune's propri

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024. The Company has two abstracts selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and another presentation showcasing data from the Phase 1 trial of RP2 combined with nivolu

WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held in San Diego, CA from April 5-10, 2024. Details of the presentations are as follows: Abstract Title: Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)Session Type: Oral PresentationSession Title: Immunotherapy Session Date and Time: Sunday, April 7,

WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following three conferences: Leerink Partners 2024 Global Biopharma ConferenceDate: Tuesday, March 12, 2024Fireside Chat Time: 2:20 pm EDT Jefferies Biotech on the Bay Miami Summit Date: Wednesday, March 13, 2024 Barclays 26th Annual Global Healthcare ConferenceDate: Thursday, March 14, 2024Fireside Chat Time: 10:45 am EDT Live webcasts of the Leerink and Barclays fireside chats w

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, wa

WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BTIG Virtual Biotechnology Conference 2023Date: Tuesday, August 8, 2023Fireside Chat Time: 1:30 pm EDT 2023 Wedbush PacGrow Healthcare Conference Date: Wednesday, August 9, 2023Location: Lotte Palace Hotel, New York, NYIn-person 1x1 investor meetings only About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in

WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's proprietary RPx platform is ba

WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023. Replimune has one abstract selected for a poster discussion session that will include updated results from the first 75 patients treated with RP1 combined with nivolumab from the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. In addition, the Company will also present data from the Phase 1 trial of RP2 combine

WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the Piper Sandler Spring Biopharma Symposium being held from Wednesday, May 17 through Thursday, May 18, 2023 at the Encore Boston Harbor in Boston, MA. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's prop

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Barclays Global Healthcare ConferenceDate: Wednesday, March 15, 2023Fireside Chat Time: 2:05 pm EDTLocation: The Loews Miami Beach Hotel, Miami, FL Jefferies Biotech on the Bay SummitLocation: 1 Hotel South Beach, Miami, FLIn-person 1x1 investor meetings only About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founde

WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with t

WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 AM PT at the Westin St. Francis Hotel in San Francisco, CA. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn,

RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%, with clinically meaningful activity across a broad range of anti-PD1 failed cutaneous melanoma settings observed, including in patients with high tumor burden and visceral disease Update, including new data, provided on the RP2/3 program Virtual investor event to be held today at 8:00 am ET WOBURN, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunot

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's proprietary RPx

WOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® in anti-PD1 failed melanoma. Additionally, the company will review the commercial opportunity in skin cancer with RP1. The Company will also provide an update on its RP2 and RP3 program. The event will begin at 8:00 a

WOBURN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO Biopharma Spotlight Series Oncology Day Date: Wednesday, November 9, 2022Fireside Chat Time: 7:30 am EST 13th Annual Jefferies Global Healthcare Conference Date: Wednesday, November 16, 2022Fireside Chat Time: 1:30 pm GMT A live webcast and replay of the fireside chat at the 13th Annual Jefferies Global Healthcare Conference will also be

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BTIG Biotechnology Conference 2022Date: Monday, August 8, 2022Fireside Chat Time: 11:00 am ET 2022 Wedbush PacGrow Healthcare Virtual ConferenceDate: Wednesday, August 10, 2022Fireside Chat Time: 9:45 am ET A live webcast and replay of the fireside chat at 2022 Wedbush PacGrow Healthcare Conference will also be available in the Investors sec

WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a p

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022. Details for the presentations are as follows: Data presentation Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE) Session Title: Melanoma/Skin CancersSession Date and Time: Monday, June 6, 2022, 1:15

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in anti-PD1 failed melanoma expected in late 2022 Phase 2 development plan for RP2/RP3 in HCC, CRC and SCCHN announced WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical activity with RP1 monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) Broad Phase 2 development planned for RP2/RP3 in hard-to-treat tumor types  Virtual investor event to be held today at 8:00 am ET WOBURN, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunot

WOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer ("NMSC") and melanoma. Additionally, the Company will present new data from the ongoing clinical trial in anti-PD1 failed NMSC and from the ARTACUS clinical trial, a Phase 1b/2 clinical trial of RP1 as monotherapy in solid organ transplant recipients with skin canc

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headqua

Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed melanoma Initial data from the ongoing study in anti-PD1 failed NMSC and from the ARTACUS trial, a Phase 1b/2 trial of RP1 as monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) RP3 initial data and the Phase 2 development plan for RP2/3 WOBURN, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, t

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with th

WOBURN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in OncologyPanel: Pioneering the Next Generation of Oncolytic Virus TherapeuticsDate: Monday, November 8, 2021Time: 12:45 pm ET Piper Sandler 33rd Virtual Annual Healthcare ConferenceDate: Tuesday, November 30 through Thursday, December, 2021A pre-recorded fireside chat will be available on-demand begin

Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022 Initial data with RP2 as monotherapy and in combination with Opdivo® (nivolumab) in patients with difficult-to-treat and anti-PD-1 failed cancers supports expanding the Phase 1 clinical trial to focus on patients whose tumors have metastasized to the liver A broad Phase 2 program with RP2 and/or RP3 with particular focus on patients with liver metastases from various prevalent cancer types is being designed with the detailed deve

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled "Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors" at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for approximately 90

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 am ET WOBURN, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic®

Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study Data update on lead programs to be provided during virtual investor event on June 3, 2021  Strengthened management team to prepare for potential commercial launch and enable further later stage development Ended fiscal year 2021 with approximately $476 million in Cash; Capitalized into second half of 2024 WOBURN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biote

WOBURN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced it will host an investor event to present updated data from its Phase 2 skin cancer cohorts combining RP1 with Opdivo® and data from its Phase 1 study of RP2 alone and in combination with Opdivo. The event will include presentations by Philip Astley-Sparke, Chief Executive Officer of Replimune, Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, and Mark Middleton, Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medi

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021. Details of the presentations are as follows: Abstract Title: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activationAbstract Number: LB180Session Title: Vaccines Session Date and Ti

WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET 33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Ti

WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on Wednesday, February 24, 2021 at 8:40 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2

WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next gene